TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Meribel Pharma Höganäs AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
179,331
|
189,705
|
154,130 |
| Financial expenses |
4,695
|
8,675
|
7,719 |
| Earnings before taxes |
-41,445
|
-16,322
|
-21,879 |
| EBITDA |
-30,149
|
-2,087
|
-10,800 |
| Total assets |
190,605
|
180,614
|
113,624 |
| Current assets |
155,867
|
142,674
|
69,936 |
| Current liabilities |
49,251
|
161,124
|
106,122 |
| Equity capital |
141,355
|
19,491
|
7,502 |
| - share capital |
103
|
101
|
95 |
| Employees (average) |
89
|
91
|
103 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
74.2%
|
10.8%
|
6.6% |
| Turnover per employee |
2,015
|
2,085
|
1,496 |
| Profit as a percentage of turnover |
-23.1%
|
-8.6%
|
-14.2% |
| Return on assets (ROA) |
-19.3%
|
-4.2%
|
-12.5% |
| Current ratio |
316.5%
|
88.5%
|
65.9% |
| Return on equity (ROE) |
-29.3%
|
-83.7%
|
-291.6% |
| Change turnover |
-13,795
|
24,639
|
37,066 |
| Change turnover % |
-7%
|
15%
|
32% |
| Chg. No. of employees |
-2
|
-12
|
-3 |
| Chg. No. of employees % |
-2%
|
-12%
|
-3% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.